Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–1545.
   PubMed Web of Science ®Google Scholar
• Hamadani M, Hari PN, Zhang Y, et al. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Nov;20(11):1729–1736.
   PubMed Web of Science ®Google Scholar
• Shah NN, Ahn KW, Litovich C, et al. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood. 2021 Mar 11;137(10):1416–1423.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2018;380(1):45–56.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155–165.
   PubMed Web of Science ®Google Scholar
• Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020 Jul;7(7):e511–e522.
   PubMed Web of Science ®Google Scholar
• Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020 Jul;21(7):978–988.
   PubMed Web of Science ®Google Scholar
• Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):790–800.
   PubMed Web of Science ®Google Scholar
• McMillan A. A new warhead in lymphoma therapy? Blood. 2021;137(19):2568–2570.
   PubMed Web of Science ®Google Scholar
• Wolska-Washer A, Robak P, Smolewski P, et al. Emerging antibody-drug conjugates for treating lymphoid malignancies. Expert Opin Emerg Drugs. 2017 Sep;22(3):259–273.
   PubMed Web of Science ®Google Scholar
• Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer. 2015 Dec 11;14:207.
   PubMed Web of Science ®Google Scholar
• Liu D. Cancer biomarkers for targeted therapy.Biomark Res. 2019 [2019 Nov 15];7(1):25.
   PubMed Web of Science ®Google Scholar
• Hartley JA. The development of pyrrolobenzodiazepines as antitumour agents.Expert Opin Investig Drugs. 2011 [2011 Jun 1];20(6):733–744.
   PubMed Web of Science ®Google Scholar
• Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634–2645.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Hamadani M, Radford J, et al. A phase I study of ADCT-402 (Loncastuximab Tesirine), a novel Pyrrolobenzodiazepine-based antibody–drug conjugate, in relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2019;25(23):6986–6994.
   PubMed Web of Science ®Google Scholar
• Jain N, Klisovic RB, Stock W, et al. Interim data from a phase 1 study evaluating Pyrrolobenzodiazepine-based antibody drug conjugate ADCT-402 (Loncastuximab Tesirine) targeting CD19 for relapsed or refractory B-cell acute lymphoblastic leukemia. Blood. 2017;130(Supplement 1):1321.
   Google Scholar
• Zammarchi F, Corbett S, Adams L, et al. ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018;131(10):1094–1105.
   PubMed Web of Science ®Google Scholar
• Hartley JA, Flynn MJ, Bingham JP, et al. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine. Sci Rep. 2018 [2018 Sep 11];8(1):10479.
   PubMedGoogle Scholar
• Caimi P, Ai W, Alderuccio JP, et al. Duration of response to loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma by demographic and clinical characteristics: subgroup analyses from LOTIS 2. Wolters Kluwer Health; 2021.
   Google Scholar
• Linhares Y, Gandhi MD, Chung M, et al. Safety and antitumor activity study evaluating Loncastuximab Tesirine and Rituximab versus immunochemotherapy in diffuse large B-cell lymphoma. Blood. 2020;136(Supplement 1):9–10.
   Google Scholar
• Hamadani M, Linhares Y, Gandhi M, et al. Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5. J clin oncol. 2021;39(15_suppl): TPS7574–TPS7574.
   PubMedGoogle Scholar
• Dreger P, Fenske TS, Montoto S, et al. Cellular immunotherapy for refractory diffuse large B cell lymphoma in the chimeric antigen receptor-engineered T cell era: still a role for allogeneic transplantation? Biol Blood Marrow Transplant. 2020 Apr;26(4):e77–e85.
   PubMed Web of Science ®Google Scholar
• Dreger P, Sureda A, Ahn KW, et al. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Adv. 2019 Feb 12;3(3):360–369.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Shippey E, Kus C, et al. Is chimeric antigen receptor T cell (CART) a destination procedure? Lower socioeconomic class who live farther from center have less access to CART. J clin oncol. 2021;39(15_suppl):e18562–e18562.
   Google Scholar
• Nastoupil LJ, Jain MD, Spiegel JY, et al. Axicabtagene Ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience. Blood. 2018 [2018 Nov 29];132(Supplement 1):91.
   Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155–165.
   PubMed Web of Science ®Google Scholar
• Phase III study shows Roche’s Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care. [Internet]. News Release;Roche;2020 [cited 2021 Aug 9];https://bit.ly/3CwmRLe
   Google Scholar
• Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978–988.
   PubMed Web of Science ®Google Scholar
• Thapa B, Caimi PF, Ardeshna KM, et al. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv. 2020;4(16):3850–3852.
   PubMed Web of Science ®Google Scholar
• Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7(7):e511–e522.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Dickinson M, Ulrickson ML, et al. Interim analysis of ZUMA-12: a phase 2 study of Axicabtagene Ciloleucel (Axi-Cel) as first-line therapy in patients (Pts) with high-risk large B cell lymphoma (LBCL). Blood. 2020;136(Supplement 1):49.
   Google Scholar